BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ...

Filsuvez is applied topically to the wound surface at home, during wound dressing changes and works to accelerate wound healing with a goal of achieving complete wound closure within 45 days. 6 "We ...

Filsuvez (birch triterpenes) is indicated to treat partial thickness wounds associated with junctional epidermolysis bullosa and dystrophic epidermolysis bullosa. The FDA has approved Chiesi Global ...

Credit: Chiesi Global Rare Diseases. Filsuvez is a sterile botanical drug product that contains a dry extract from 2 species of birch bark. Findings showed 41.3% of patients treated with Filsuvez had ...

The data package for Filsuvez (birch triterpenes), a topical gel aimed at treating partial thickness wounds, satisfied U.S. reviewers the second time around. Chiesi Group said the FDA approved the ...

Filsuvez (birch triterpenes) Botanical drug product (birch bark extract) Topical gel for the treatment of partial thickness wounds in patients 6 months of age and older with junctional epidermolysis ...

FILSUVEZ topical gel is indicated for the treatment of partial thickness wounds in patients 6 months and older with Junctional and Dystrophic Epidermolysis Bullosa (EB) FILSUVEZ was well tolerated and ...

Please provide your email address to receive an email when new articles are posted on . Filsuvez is a topical gel made from a dry extract from two species of birch bark. A phase 3 trial found complete ...

(MENAFN- PR Newswire) PITTSBURGH, Feb. 5, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it was ...